Jeffries: Results from Novo Nordisk's Flow study in line with expectations
Jefferies hopes that Novo Nordisk will present more detailed results this week at the company’s capital markets day.
by MARKETWIRE
The results from Novo Nordisk’s Flow study came out in line with the expectations of investment firm Jefferies, which believes that a demonstrated reduction in the risk of kidney disease-related events in people with type 2 diabetes with chronic kidney disease may disappoint against the most aggressive expectations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
